dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Ravimiamet
Väljaminev kiriAvalik

Answers to Query

Ravimiamet · 15. juuli 2024
Viit
JUR-1/635-2
Registreeritud
15. juuli 2024
Dokumendi liik
Väljaminev kiri
Adressaat
Clinigen Group
Saabumis/saatmisviis
Outlook
Funktsioon
JUR Õigusalane nõustamine
Sari
JUR-1 Kirjavahetus õigusküsimustes
Toimik
JUR-1/2024
Vastutaja
Jaanika Reimaa (RA, Järelevalveosakond, Sisse- ja väljaveo järelevalve büroo)

Failid

  • 📎E-kiri - 2024-07-15T135852.802.eml94 KB

Sisu (failidest)

Saatja: "Jaanika Reimaa" <[email protected]> Saaja: "Kärolin Jenas" <[email protected]> Teema: Ed: Medicinal Products Act / Import authorisation query (unlicensed medicines) Kuupäev: 2024-07-15 10:12 Saatja: Eriluba Saatmisaeg: neljapäev, 25. jaanuar 2024 16:48 Adressaat: 'Jenna Bruce' <[email protected] <mailto:[email protected]> > Teema: Vs: Medicinal Products Act / Import authorisation query (unlicensed medicines) Dear Jenna, Thank you for the enquiry. Yes, you have understood correctly the following: * An import permit is required when importing a product, which does not have a marketing authorisation in any of the EEA member states. * An import permit is not required when importing a product from another EEA member state, which has a marketing authorisation in another EEA member state (instead the medicines agency should be notified no later than 5 working days after the import). UK is not part of EEA anymore, which means that import permit is required when importing unlicensed medicinal product from UK to Estonia, regardless whether it has a marketing authorisation in any EEA member state. Please let me know it you have any further questions. With best regards Jaanika Reimaa Specialist Bureau of Import and Export Supervision Department of Supervision State Agency of Medicines <mailto:[email protected]> [email protected] 1 Nooruse Street 50411 Tartu Estonia Phone: +372 737 4140 <http://www.ravimiamet.ee/> www.ravimiamet.ee This e-mail and any attachments transmitted may contain confidential and privileged information. If you are not the intended recipient, please notify the sender immediately by returning the e-mail and permanently deleting what you have recieved. Any dissemination or use of this information by a third person without permission is prohibited and may be illegal. Saatja: Jenna Bruce <[email protected] <mailto:[email protected]> > Saatmisaeg: kolmapäev, 24. jaanuar 2024 16:18 Adressaat: Ravimiamet <[email protected] <mailto:[email protected]> >; Eriluba <[email protected] <mailto:[email protected]> > Koopia: Clinigen Regulatory Affairs <[email protected] <mailto:[email protected]> > Teema: Medicinal Products Act / Import authorisation query (unlicensed medicines) Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. Dear State Agency of Medicine, I am contacting you as a Senior Regulatory Affairs Associate at Clinigen with an enquiry in relation to the import of medicinal products in to Estonia according to the Medicinal Products Act. We understand that in order to import an unlicensed drug in to Estonia: * An import permit is required where the product does not have a marketing authorisation in any of the EEA member states * An import permit is not required where the product has a marketing authorisation in an EEA member state (instead the medicines agency should be notified no later than 5 working days after the import) Please can you kindly clarify if an import permit is required when importing an unlicensed drug into Estonia, where the product is authorised in the UK (and supplied in UK commercial packaging): a. In the case that there is a marketing authorisation for the same active substance/pharmaceutical form in an EEA member state b. If there is not a marketing authorisation for the same active substance/pharmaceutical form in an EEA member state The UK are no longer part of the EEA however our understanding is that wholesalers in Estonia may refer to EMA’s Article 57 database ( <https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database> https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database) to determine if an import permit is required, and this database still includes products with a marketing authorisation in the UK. Thank you in advance. Kind regards, Jenna Jenna Bruce Regulatory Affairs Associate t: +44 1932 824000 m: +44 7880 201227 e: [email protected] <mailto:[email protected]> <https://www.clinigengroup.com/> <https://www.clinigengroup.com/> clinigen.com <https://twitter.com/Clinigen> <https://www.linkedin.com/company/clinigen> The information you need, directly to you: <https://www.clinigengroup.com/company/newsroom/stay-in-touch> Sign-up for our tailored news alerts This email (and any attachments) is intended solely for the addressee. It is confidential and may be subject to copyright. It may contain legally privileged or proprietary information. If you are not the intended addressee, immediately notify the sender, permanently delete it and do not read, use, copy, store, disclose or rely on the information contained in this email (or any attachment). Emails sent to and from Clinigen Limited and/or its subsidiaries (“Clinigen”) may be monitored and read for legitimate business purposes, including compliance with the law and our regulatory obligations. Emails and their attachments cannot be guaranteed to be secure or error-free: you should protect your systems. Clinigen cannot accept responsibility for any loss or damage sustained as a result of computer viruses and the recipient must ensure that the email (and attachments) are virus free. Clinigen does not accept any liability arising from delay, interception, corruption, loss or destruction of this email (including any attachment), or received incomplete or with viruses. Your privacy is important to us. Please see our <https://www.clinigengroup.com/privacy-policy> Privacy Policy for further details. Clinigen Limited is a private limited company (registered in England and Wales with registered number 06771928) whose registered office is at Pitcairn House, Crown Square, Centrum 100. Burton-on-Trent, Staffordshire, DE14 2WW. Clinigen Limited’s subsidiary trading companies registered in England and Wales can be found <https://www.clinigengroup.com/subsidiaries> here.
Allikas: Ravimiamet dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel